{
    "clinical_study": {
        "@rank": "141136", 
        "acronym": "Hepburn", 
        "arm_group": [
            {
                "arm_group_label": "unfractionated heparin", 
                "arm_group_type": "Experimental", 
                "description": "25.000 IU/5 ml, will be nebulized 4 hourly (i.e. 6 times daily)"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Sterile sodium chloride (NaCl 0.9%, Pfizer), in 5 ml, will be nebulized every 4 hours (i.e. 6 times daily)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this international multi-center double-blind randomized placebo-controlled\n      trial is to determine the effect of  nebulized heparin, compared to placebo, on the number\n      of ventilator-free days at day 28, in burn patients with confirmed inhalation trauma\n      requiring mechanical ventilation."
        }, 
        "brief_title": "Trial of Nebulized Heparin Versus Placebo for Inhalation Trauma", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Inhalation Injury", 
            "Burn Injury"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Respiratory Aspiration", 
                "Burns", 
                "Wounds and Injuries"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Informed consent\n\n          -  Age > 18 years\n\n          -  Need for invasive mechanical ventilation\n\n          -  Confirmed inhalation trauma (bronchoscopically)\n\n        Exclusion Criteria:\n\n          -  > 36 hours after trauma\n\n          -  Receiving invasive ventilation > 24 hours\n\n          -  Expected duration of mechanical ventilation < 24 hours\n\n          -  Chronic obstructive pulmonary disease GOLD stage III and IV\n\n          -  Any history of pulmonary hemorrhage in the past 3 months\n\n          -  Any history of significant bleeding disorder\n\n          -  Known allergy to heparin, including heparin-induced thrombocytopenia\n\n          -  Pregnancy or breast feeding\n\n          -  Unlikely to survive for > 72 hours\n\n          -  Total body surface area (TBSA) > 60%\n\n          -  Witnessed or proven aspiration (i.e., confirmed by bronchoscopy)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "116", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01773083", 
            "org_study_id": "HepBurn", 
            "secondary_id": "2012-003289-42"
        }, 
        "intervention": [
            {
                "arm_group_label": "unfractionated heparin", 
                "description": "nebulized 6 times daily, daily dose 150.000 IU for the maximum duration of 14 days", 
                "intervention_name": "unfractionated heparin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "unfractionated heparin sodium, EV Product Code: SUB02475MIG,", 
                    "Marketing Authorisation number: RVG 01372", 
                    "ATC codes: B01AB01"
                ]
            }, 
            {
                "arm_group_label": "placebo", 
                "description": "Placebo: Sterile saline nebulized 6 times daily for the maximum duration of 14 days", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug", 
                "other_name": "sterile sodium chloride (NaCl 0.9%)"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Calcium heparin", 
                "Heparin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Inhalation trauma", 
            "pulmonary coagulopathy", 
            "heparin nebulization", 
            "mechanical ventilation"
        ], 
        "lastchanged_date": "February 21, 2014", 
        "location": [
            {
                "contact": {
                    "email": "barry.dixon@svhm.org.au", 
                    "last_name": "Barry Dixon, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Melbourne", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3065"
                    }, 
                    "name": "St Vincent's Hospital"
                }, 
                "investigator": {
                    "last_name": "Barry Dixon, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Kirsten"
                }, 
                "contact_backup": {
                    "email": "kirsten.colpaert@ugent.be", 
                    "last_name": "Colpaert, MD, Dr."
                }, 
                "facility": {
                    "address": {
                        "city": "Gent", 
                        "country": "Belgium", 
                        "state": "Oost-Vlaanderen", 
                        "zip": "9000"
                    }, 
                    "name": "University Hospital, Gent"
                }, 
                "investigator": {
                    "last_name": "Kirsten Colpaert, MD, Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "jan.muller@uzleuven.be", 
                    "last_name": "Jan Muller, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium", 
                        "state": "Vlaams-Brabant", 
                        "zip": "3000"
                    }, 
                    "name": "University Hospital Gasthuisberg - Leuven"
                }, 
                "investigator": {
                    "last_name": "Jan Muller, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Manu.Malbrain@zna.be", 
                    "last_name": "Manu Malbrain, MD, Dr."
                }, 
                "facility": {
                    "address": {
                        "city": "Antwerpen", 
                        "country": "Belgium", 
                        "zip": "2000"
                    }, 
                    "name": "Ziekenhuis Netwerk Antwerpen- Stuivenberg"
                }, 
                "investigator": {
                    "last_name": "Manu Malbrain, MD, Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "state": "Noord-Holland", 
                        "zip": "1105 AZ"
                    }, 
                    "name": "Academic Medical Center"
                }, 
                "investigator": [
                    {
                        "last_name": "Marcus J Schultz, Prof. Dr.", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Koenraad F van der Sluijs, Dr.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Gerie J Glas, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Marcel M Levi, Prof. Dr.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Nicole P Juffermans, Dr. MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "pknape@rkz.nl", 
                    "last_name": "Paul Knape, MD"
                }, 
                "contact_backup": {
                    "email": "sd.mackie@wxs.nl", 
                    "last_name": "David P Mackie, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Beverwijk", 
                        "country": "Netherlands", 
                        "state": "Noord-Holland", 
                        "zip": "1942 LE"
                    }, 
                    "name": "Red Cross Hospital, Beverwijk, the Netherlands"
                }, 
                "investigator": [
                    {
                        "last_name": "Paul Knape, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "David P Mackie, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "cleffkenb@maasstadziekenhuis.nl", 
                    "last_name": "Barry Cleffken, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands", 
                        "state": "Zuid-Holland", 
                        "zip": "3079 DZ"
                    }, 
                    "name": "Maasstad Hospital"
                }, 
                "investigator": {
                    "last_name": "Barry Cleffken, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "b.loef@mzh.nl", 
                    "last_name": "Bert G Loef, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Groningen", 
                        "country": "Netherlands", 
                        "zip": "9728 NT"
                    }, 
                    "name": "Martini Hospital"
                }, 
                "investigator": {
                    "last_name": "Bert G Loef, MD, Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Australia", 
                "Belgium", 
                "Netherlands"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Controlled Trial Investigating the Efficacy and Safety of Nebulized Heparin Versus Placebo in Burn Patients With Inhalation Trauma (Hepburn)", 
        "overall_contact": {
            "email": "g.j.glas@amc.uva.nl", 
            "last_name": "Gerie J Glas, MD", 
            "phone": "00 31 20 5668222"
        }, 
        "overall_contact_backup": {
            "email": "KvanderSluijs@amc.uva.nl", 
            "last_name": "Koenraad F van der Sluijs, Dr.", 
            "phone": "00 31 20 5669111"
        }, 
        "overall_official": [
            {
                "affiliation": "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)", 
                "last_name": "Marcus J Schultz, Prof. Dr., MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)", 
                "last_name": "Koenraad F van der Sluijs, Dr.", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "the Netherlands: Central Committee on Research inv. Human Subjects (CCMO)", 
                "the Netherlands: Institutional Review Board Amsterdam", 
                "Belgium: Federal Agency for medicines and health products (FAGG)", 
                "Belgium: Institutional Review Board (Leuven, Ghent, Antwerp; status: to be requested)"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The number of ventilator-free days is defined as the number of days a patient is breathing without assist of a ventilator during the first 28 days; thus, the patient must be free of mechanical ventilation for 24 hours to have one ventilator-free day; if after successful detubation the patient requires a reintubation due to a surgical procedure, this reintubation will not count as a ventilator day - however, the day(s) will be counted as ventilator day(s) if mechanical ventilation is prolonged after surgery due to respiratory insufficiency.", 
            "measure": "Number of ventilator-free days at day 28", 
            "safety_issue": "No", 
            "time_frame": "at day 28"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01773083"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)", 
            "investigator_full_name": "Marcus J Schultz", 
            "investigator_title": "Prof. Dr.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Clinical outcome parameters will include but not be restricted to: (a) length of stay (ICU and hospital); (b) mortality (28- and 90 days); (c) mortality (ICU and hospital); (d) daily Lung Injury Score (LIS); (e) daily Oxygenation Index (OI) ; (f) daily Sequential Organ Failure Assessment (SOFA)-scores ; (g) cumulative dosages of sedatives; (h) incidence of Ventilator-associated Pneumonia (VAP); (i) total number of bronchoscopy-guided cleaning of the larger airway", 
                "measure": "Clinical outcome parameters", 
                "safety_issue": "No", 
                "time_frame": "daily or at day 28 and day 90"
            }, 
            {
                "description": "Levels of markers of coagulation and fibrinolysis in blood and lung lavage fluid, Levels of markers of inflammation in blood and lung lavage fluid, Biomarkers of lung injury in blood and lung lavage fluid", 
                "measure": "Laboratory outcome parameters", 
                "safety_issue": "No", 
                "time_frame": "Blood and lavage samples: on admission day and every other day for a maximum period of 14 days"
            }, 
            {
                "description": "Safety parameters will include but not be restricted to: Occurrence of serious bleedings, any other transfusion of blood products - red cells and/or platelets and/or plasma, Confirmed Heparin induced thrombocytopenia, prolonged activated partial thromboplastin time (aPTT > 150 seconds)", 
                "measure": "Safety parameters", 
                "safety_issue": "Yes", 
                "time_frame": "daily, for a maximum period of 28 days"
            }
        ], 
        "source": "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)", 
        "sponsors": {
            "collaborator": {
                "agency": "Dutch Burns Foundation", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}